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Maintenance of hematopoietic stem cells
(HSCs) depends on interaction with their niche.
Here we show that the long-term (LT)-HSCs ex-
pressing the thrombopoietin (THPO) receptor,
MPL, are a quiescent population in adult bone
marrow (BM) and are closely associated with
THPO-producing osteoblastic cells. THPO/
MPL signaling upregulated b1-integrin and cy-
clin-dependent kinase inhibitors in HSCs. Fur-
thermore, inhibition and stimulation of THPO/
MPL pathway by treatments with anti-MPL
neutralizing antibody, AMM2, and with THPO
showed reciprocal regulation of quiescence of
LT-HSC. AMM2 treatment reduced the number
of quiescent LT-HSCs and allowed exogenous
HSC engraftment without irradiation. By con-
trast, exogenous THPO transiently increased
quiescent HSCpopulation and subsequently in-
duced HSC proliferation in vivo. Altogether,
these observations suggest that THPO/MPL
signaling plays a critical role of LT-HSC regula-
tion in the osteoblastic niche.
INTRODUCTION
HSCs self-renew and differentiate to produce multilineage
blood cells throughout an individual’s lifetime. Mainte-
nance of such stem cell activities requires both intrinsic
and extrinsic factors. For HSCs, these factors are pro-
vided by the microenvironment called the stem cell niche.
Cell-cell, cell-extracellular matrix, and receptor-ligand in-
teractions occur between HSCs and the niche (Li and
Xie, 2005; Adams and Scadden, 2006; Li and Li, 2006;
Moore and Lemischka, 2006; Wilson and Trumpp, 2006).CellSuch interaction of HSCs with the niche is critical to main-
taining the balance between proliferation and quiescence,
which is a common stem cell property with respect to the
cell cycle. Cell-cycle quiescence is essential for long-term
preservation of stem cell properties, including self-re-
newal capacity and the ability to differentiate into multiple
lineages (Cheng et al., 2000).
We recently clarified a molecular mechanism whereby
the cell cycle of HSCs is regulated by the osteoblastic
niche in BM (Arai et al., 2004). Cell-cycle regulation by
the niche is critical for HSC fate. We previously reported
that LINSCA1hiKIThi (LSK) cells in peripheral blood and
spleen mobilized by G-CSF were not in the side popula-
tion (SP) (Arai et al., 2004), indicating that HSCs exited
from the BM niche are not in G0. We found that quiescent
HSCs adhere to osteoblastic cells in the BM niche and
showed that interaction of the Tie2 receptor with its ligand
angiopoietin-1 (Ang-1) leads to tight adhesion of HSCs to
the osteoblastic niche, resulting in maintenance of quies-
cence (Arai et al., 2004). Currently, various molecules in-
volved in the signaling and adhesive interaction between
HSCs and the BM niche are identified (Yin and Li, 2006).
In this study, we showed that THPO/MPL signaling is
a candidate niche factor.
Signaling via THPO and its receptor, MPL, regulates
megakaryogenesis (Kaushansky, 1995). MPL was identi-
fied as the product of the c-MPL gene, the wild-type ho-
molog of the oncogene v-MPL, the transforming gene of
murine myeloproliferative leukemia virus (Vigon et al.,
1992). THPO acts as both a megakaryocyte colony-stim-
ulating and maturation factor in megakaryopoiesis (de
Sauvage et al., 1994; Lok et al., 1994; Wendling et al.,
1994). In megakaryopoiesis, THPO/MPL interaction pri-
marily stimulates late megakaryocytic colony-forming
units, consequently increasing the number of mature
megakaryocytes with the capacity to form proplatelets.
Initially, THPO/MPL signaling was identified as the primary
regulator of platelet production (Kaushansky, 1995), andStem Cell 1, 685–697, December 2007 ª2007 Elsevier Inc. 685
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Regulation of Quiescent HSCs by THPOMPL later revealed its role closely related to HSC function
(Kimura et al., 1998; Solar et al., 1998; Buza-Vidas et al.,
2006). THPO orMPL knockout mice exhibit not only signif-
icantly fewer megakaryocytes and circulating platelets
(Gurney et al., 1994; de Sauvage et al., 1996) but also
show fewer HSCs in the BM (Carver-Moore et al., 1996;
Alexander et al., 1996; Kimura et al., 1998). MPL/ mice
showed the decrease of numbers of progenitor cells in
multilineage and reduction of competitive repopulating
capacity (Carver-Moore et al., 1996; Alexander et al.,
1996; Kimura et al., 1998). In addition, hyperresponsive-
ness to THPO seen in mice lacking the adaptor protein
Lnk results in HSC expansion (Buza-Vidas et al., 2006).
Like other hematopoietic cytokines, THPO activates three
major signaling pathways: p42/44 mitogen-activated pro-
tein kinase (MAPK) (Rojnuckarin et al., 1999), phosphoino-
sitide 3-kinase-Akt (Geddis et al., 2001), and Janus kinase
(JAK)-signal transducer, and activator of transcription
(STAT) 3 and STAT5 (Dorsch et al., 1995; Drachman et al.,
1995). Although these signaling pathways have been
broadly studied in the context of megakaryopoiesis, the
role of THPO/MPL signaling in the interaction of quiescent
HSCs with the niche is still unknown.
Here we identified that LSKCD34MPL+ cells and
LSKCD34+MPL+ cells are regarded as quiescent and ac-
tive HSCs, respectively. In addition, both LSKCD34MPL+
and LSKCD34+MPL+ cells had the ability for long-term BM
reconstitution (LTR). Further, we found that quiescent
MPL+ HSCs adhered to THPO-producing osteoblastic
cells on the endosteal surface. Such positional associa-
tion between MPL+ HSC and THPO+ osteoblastic cells
suggests that THPO/MPL signaling contributes to regula-
tion of quiescent LT-HSCs in the osteoblastic niche. We
also investigated the physiological role of THPO/MPL sig-
naling in regulating HSCs in the niche using an anti-MPL
neutralizing antibody (Ab) and recombinant THPO. Inhibi-
tion of the THPO/MPL pathway with a neutralizing anti-
MPL Ab reduced the number of quiescent HSCs and
HSC-niche interaction. On the other hand, exogenous
THPO transiently increased the proportion of quiescent
HSCs in vivo. These observations indicate that THPO
and MPL in HSCs play a role in the maintenance of quies-
cence of HSCs in the niche.
RESULTS
Quiescent HSCs Express MPL
Although MPL expression in HSCs has been demonstrated
(Berardi et al., 1995; Solar et al., 1998), the function of MPL
in thiscontext remains unclear. To analyze that function, we
examined first the MPL expression in subsets of LSK cells.
It has been shown that LT-HSCs are enriched in the
CD34FLT3Tie2+ or CD48CD150+ fractions in LSK cells
(Osawa et al., 1996; Hsu et al., 2000; Adolfsson et al., 2001;
Christensen and Weissman, 2001; Arai et al., 2004; Kiel
et al., 2005). Therefore, we analyzed the proportion of
MPL+ cells in LT-HSCs (Figure 1A). MPL+Tie2+ cells were
enriched in LSKCD34FLT3 cells. In LSKCD48 cells,
MPL+ cells were divided into CD150+ and CD150 cells.686 Cell Stem Cell 1, 685–697, December 2007 ª2007 ElsevieThe percentages of MPL+ cells in LSKCD34FLT3Tie2+
and LSKCD48CD150+ cells were 96.4% ± 1.7% and
97.2% ± 3.6%, respectively, suggesting that MPL is ex-
pressed in LT-HSCs and may play a role in LTR activity.
Next, we analyzed the expression of MPL in SP cells in
LSK. SP and non-SP phenotypes in LSK cells represent
quiescent and cycling HSCs, respectively (Arai et al.,
2004). FACS analysis showed that 85.6% ± 2.3% of LSK-
SP cells express MPL (Figure 1B). To investigate the poten-
tial relevance of MPL expression to HSC cell-cycle status,
we analyzed the proportion of LSK-MPL+ cells after 5-fluo-
rouracil (5-FU)-induced myelosuppression (Figure 1C). Af-
ter 2 days of 5-FU treatment, the remaining LSK cells were
MPL positive (82.1% ± 6.1% of LSK cells), whereas LSK-
MPL cells were susceptible to 5-FU treatment, which
are similar findings to the case of LSK-SP cells, as previ-
ously reported (Arai et al., 2004). After 6 days of 5-FU treat-
ment, the proportion of LSK-SP cells was reduced, and the
population of LSK cells shifted from SP to non-SP. Similar
to the change of SP, MPL expression was downregulated
(44.6% ± 5.1%) after 6 days of 5-FU treatment.
Next, to clarify the changes of cell-cycle regulators, we
examined the expression of cyclin-dependent kinase inhib-
itors (Cdkns), c-Myc, and Tie2 in LSKCD34+ or MPL+ or 
cells. As shown in Figure 1D, p57Kip2 (Cdkn1c) was mark-
edly expressed in CD34MPL+ fraction in LSK, and Tie2
was expressed in MPL+ fraction in LSK regardless of
CD34 expression. In addition, p57Kip2 was highly ex-
pressed in LSK-SP cells (see Figure S1 in the Supplemental
Data available with this article online). Altogether, these
data suggest that MPL is expressed in the quiescent
LT-HSCs in adult BM.
MPL+ HSCs Adhere to the Endosteal Surface,
and Osteoblastic Cells Produce THPO in Adult BM
We previously reported that Tie2 is a marker for LT-HSCs
and that 5-FU-resistant Tie2+ cells are quiescent HSCs in
the osteoblastic niche (Arai et al., 2004). Thus, we exam-
ined expressions of MPL in 5-FU-treated BM to define
the localization of MPL+ HSCs along with Tie2 in BM
(Figure 2A). 5-FU-resistant Tie2+MPL+ cells were localized
to the endosteal surface, where osteoblasts reside, sug-
gesting that MPL+HSCs are localized in the osteoblastic
niche. To further confirm whether 5-FU-resistant MPL+
cells are in quiescence, we performed BrdU long-term la-
bel-retaining (BrdU-LTR) cell assay. BrdU-LTR is a marker
for identification of quiescent cells in tissue (Zhang et al.,
2003). As shown in Figure 2B, BrdU-LTR cells expressed
MPL and adhered to bone-lining cells in 5-FU-treated
BM. These data suggest that 5-FU-resistant MPL+ HSCs
are quiescent HSCs in the osteoblastic niche.
Osteoblastic cells are the key component of the HSC
niche, and quiescent HSCs specifically localize to the end-
osteal surface of adult BM (Nilsson et al., 2001; Calvi et al.,
2003; Zhang et al., 2003; Arai et al., 2004). Therefore, we
analyzed THPO expression in BM. Immunohistochemical
staining of THPO in BM showed that a subset of bone-lin-
ing alkaline phosphatase (ALP)-positive osteoblastic cells
express THPO (Figure 2C), suggesting that THPO isr Inc.
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Regulation of Quiescent HSCs by THPOFigure 1. MPL Is Highly Expressed on Quiescent LT-HSCs
(A) The proportion of MPL+ cells in the fraction of LSKCD34FLT3Tie2+ cells and LSKCD48CD150+ cells. Expression of MPL and Tie2 in
LSKCD34FLT3 cells (Aa). LSKCD34FLT3Tie2+ cells were gated and analyzed for the frequency of MPL+ cells (Ab). Expression of MPL and
CD150 in LSKCD48 cells (Ac). LSKCD48CD150+ cells were gated and analyzed the frequency of MPL+ cells (Ad). Most CD34FLT3Tie2+ and
CD48CD150+ fractions in LSK cells express MPL. Dotted lines indicate isotype-matched control. Data represent mean ± SD (n = 4).
(B) The proportion of MPL+ cells in quiescent and active states. Expression of MPL in LSK-SP (red) and LSK-non-SP cells (light blue) was analyzed.
LSK-SP cells showed a high percentage of the MPL+ fraction compared to LSK-non-SP cells. Dotted lines indicate isotype-matched control. Data
represent mean ± SD (n = 4).
(C) Changes in the proportion of LSK-SP (upper) and LSK-MPL+ (lower) cells after 5-FU treatment. Both of the SP and MPL+ cells in LSK were enriched
2 days after 5-FU injection, while non-SP and MPL cells were reduced. On day 6 after 5-FU treatment, a shift in the LSK population from SP to non-
SP was observed. At the same time, MPL expression in LSK cells was downregulated on day 6 after 5-FU injection. Dotted lines indicate isotype-
matched control. Data represent mean ± SD (n = 4). Representative data of a series of experiments are shown.
(D) Expression of p21Cip1, p27Kip1, p57Kip2, c-Myc, and Tie2 in LSKCD34+ or MPL+ or  fractions. Data represent mean ± SD from two independent
experiments.produced in the microenvironment of osteoblastic niche
cells. In addition, 5-FU-resistant MPL+ cells adhered to
the THPO-producing osteoblastic cells on the bone sur-
face (Figure 2D). Quantitative PCR (qPCR) confirmed
that THPO was expressed in the BM-derived osteoblastic
cell clones (Figure 2E). These data suggest that THPO/
MPL signaling between osteoblastic cells and HSCs is in-
volved in the niche regulation of HSCs, and the cell adhe-
sion of MPL+ HSCs to THPO+ osteoblastic cells might
contribute to the maintenance of quiescent HSCs in the
osteoblastic niche.
MPL in LSK Cells Is a Specific Marker for LT-HSCs
Since MPL expression in a subset of LSK cells corre-
sponded to the known LT-HSC population, we hypothe-Cell Ssized that THPO/MPL signaling was physiologically in-
volved in the HSC function. Then we examined whether
expression of MPL in HSCs contributes to LTR activity.
First we compared BM reconstitution capacity between
MPL+ and MPL fraction in LSK cells. As shown in
Figure 3A, the cells that have LTR activity were enriched
in MPL+ fraction in LSK fraction. In addition, MPL+ cells
showed remarkable repopulation after the second BM
transplantation (BMT) (Figure 3B). For further evaluation
of the role of MPL in LT-HSC and ST-HSC population,
we subdivided LSK cells into four fractions (CD34MPL+,
CD34+MPL+, CD34MPL, and CD34+MPL) and exam-
ined LTR activity (Figure 3C). It has been reported that
LT-HSCs were enriched in CD34 fraction in LSK cells
(Osawa et al., 1996). We found that MPL+ fraction hadtem Cell 1, 685–697, December 2007 ª2007 Elsevier Inc. 687
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Regulation of Quiescent HSCs by THPOFigure 2. Localization of MPL+ HSCs and THPO-Expressing Osteoblastic Cells in the Trabecular Bone Area of BM
(A) Immunohistochemical staining of Tie2 (green) and MPL (red) in 5-FU treated BM. (Aa, Ac, Ae) Multiple views of the trabecular bone surface. (Ab, Ad,
Af) Higher magnifications of enclosed boxes in (Aa), (Ac), and (Ae), respectively. MPL+Tie2+ HSCs adhered to the endosteal surface (arrowheads).
Scale bars, 10 mm (Aa, Ac, Ae), 3 mm (Ab, Ad, Af).
(B) Expression of MPL in BrdU-LTR cells. (Ba) Lower magnification. (Bb) Higher magnifications of enclosed boxes in (Ba). Scale bar, 3 mm.
(C) Expression of THPO in trabecular bone area of adult mouse BM. (Ca–Cc) Lower magnification. (Cd–Cf) Higher magnifications of enclosed boxes in
(Ca)–(Cc), respectively. (Ca and Cd) Expression of ALP (green). (Cb and Ce) Expression of THPO (red). (Cc and Cf) Merged images of (Ca) and (Cb) and
(Cd) and (Ce), respectively. THPO expression was detected in the ALP+ bone-lining osteoblastic cells (arrowheads). Scale bar, 100 mm (Ca–Cc), 25 mm
(Cd–Cf).
(D) Expression of THPO (green) and MPL (red) in 5-FU treated BM. (Da and Dc) Multiple views of the trabecular bone surface. (Db and Dd) Higher
magnifications of enclosed boxes in (Da) and (Dc), respectively. 5-FU-resistant MPL+ HSCs were adhered to THPO-producing bone-lining cells
(arrowheads). Scale bar, 15 mm.
(E) qPCR analysis of osteocalcin (Ocn) and THPO expression in NIH 3T3 cells and BM-derived osteoblastic cells. THPO expression was expressed
highly in osteocalcin-expressing osteoblastic cells compared to NIH 3T3 cells. Data represent mean ± SD from three independent experiments.significantly higher LTR activity than MPL fraction in
LSKCD34 cells (Figure 3C). Peripheral blood analyses
showed that the donor-derived LSKCD34MPL+ cells dif-
ferentiated into myeloid, B cell, and T cell lineages
(Figure 3D). These data suggest that LT-HSC was pre-
dominantly enriched in LSKCD34MPL+ cells. Unexpect-
edly, MPL+ cells in LSKCD34+ cells, which were thought
short-term (ST)-HSCs, clearly showed lymphomyeloid re-
constitution (Figures 3C and 3D), even though the periph-
eral blood chimerism was lower than LSKCD34MPL+
cells. These data indicate that MPL is an effective marker
for LT-HSCs. This result can contribute to establishment688 Cell Stem Cell 1, 685–697, December 2007 ª2007 Elsevierof a novel cell purification strategy of LT-HSCs, with which
higher purity is achievable than with currently available
protocol.
THPO/MPL Signaling Maintains an Immature
Phenotype in HSCs
To investigate the function of THPO/MPL signaling in HSC
maintenance in vitro, we performed long-term colony-
initiating cell (LTC-ICs) assays and cobblestone area-
forming cell (CAFCs) assays with or without the anti-MPL
neutralizing Ab, AMM2. AMM2 did not inhibit colony forma-
tion of freshly isolated LSK cells (Figure 4A), while AMM2Inc.
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Regulation of Quiescent HSCs by THPOFigure 3. LT-HSCs Were Enriched in MPL+ Fraction
(A) MPL+ (B) and MPL (C) fractions of LSK cells were sorted from 8-week-old mice BMMNCs and transplanted into lethally irradiated mice. Per-
centages of donor-derived (Ly5.1+) cells in recipient mice 1–6 months after BMT. Red lines indicate mean percentages of donor-derived cells. The
data shown represent mean ± SD (n = 7 per group).
(B) BMMNCs (left) or LSK cells (right) were isolated from LSK-MPL+ (B) or MPL (C) transplanted primary recipient mice and secondary transplanted
into lethally irradiated mice. Percentages of donor-derived (Ly5.1+) cells in secondary recipient mice 1–3 months after BMT.
(C) Eight-week-old mice derived LSKCD34+ or MPL+ or  cells (upper panel) were transplanted into lethally irradiated recipient mice. Remarkable
long-term reconstitution was seen in LSKCD34MPL+ cells (lower panel). Data represent mean ± SD (n = 10 per group).
(D) Peripheral blood analysis of B, T, and myeloid cell lineages 4 months after BMT of LSKCD34+ or MPL+ or  cells.inhibited the maintenance of LTC-IC on OP9 stromal cells
(Figure 4B). These data suggest that THPO/MPL signaling
maintains immature HSC phenotypes in vitro.
We analyzed the function of THPO/MPL signaling in
HSC cobblestone formation. To do so, we cocultured
LSK-MPL+ cells and OP9 stromal cells in the presence
of THPO or AMM2 and evaluated CAFCs. As shown in
Figure 4C, exogenous THPO enhanced cobblestone for-
mation 3-fold in LSK-MPL+ cells compared to stem cell
factor (SCF) alone. By contrast, AMM2 inhibited adhesion
of LSK-MPL+ cells and reduced CAFCs in a dose-depen-
dent manner. In addition, THPO upregulated b1-integrin
expression in LSK-MPL+ cells compared to SCF alone
(Figure 4D). It has been shown that THPO activated b1-in-
tegrin in a human progenitor cell line and CD34+CD38
cells (Cui et al., 1997). Altogether, these data suggest
that THPO/MPL signaling preserves immature pheno-
types in HSCs via interaction with stromal cells.Cell SEffects of THPO/MPL Signaling in the Regulation
of Cell-Cycle-Related Genes in HSCs
Next, we examined the effects of THPO/MPL signaling on
the expression of cell-cycle regulators. First, we examined
effects of administration of AMM2 or THPO in vivo on ex-
pression of Cdkns (p21Cip1, p27Kip1, and p57Kip2), c-Myc,
and Tie2 in LSK cells. AMM2 and THPO treatment re-
vealed a reciprocal correlation with expression of p57kip2
(increased by THPO, decreased by AMM2), c-Myc (de-
creased by THPO, increased by AMM2), and Tie2
(increased by THPO, decreased by AMM2) (Figure 5A).
In addition, p21Cip1 expression was slightly upregulated
by THPO. Next, we examined the effects of THPO treat-
ment on LSKCD34MPL+ and LSKCD34+MPL+ cells
in vitro and found that THPO maintained the expression
levels of p57Kip2, c-Myc, and Tie2 in LSKCD34MPL+ cells
(Figure 5B). Although THPO treatment upregulated
p57Kip2 and Tie2 in LSKCD34+MPL+ cells, the stimulationtem Cell 1, 685–697, December 2007 ª2007 Elsevier Inc. 689
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Regulation of Quiescent HSCs by THPOFigure 4. Role of THPO/MPL Signaling in
HSC Maintenance In Vitro
(A) Numbers of CFU-C in the culture with or
without AMM2.
(B) Numbers of LTC-IC. LSK cells (500 cells per
well) were cocultured with OP9 stromal cells in
the presence or absence of AMM2 (100 ng/ml
or 1 mg/ml). Colony assays were performed af-
ter 2–6 weeks of coculture. Data represent
mean ± SD (*p < 0.01, **p < 0.05).
(C) Numbers of CAFCs. LSK-MPL+ cells were
sorted and cultured on OP9 stromal cells in
the presence of SCF with or without THPO or
AMM2. After 7 days of cultivation, numbers of
CAFCs were counted. THPO increased the
number of CAFCs, whereas AMM2 decreased
CAFCs in a dose-dependent manner. Data
represent mean ± SD.
(D) Relative expression of b1-integrin after
in vitro culture of LSK-MPL+ cells with SCF or
SCF and THPO was analyzed by qPCR. Ex-
pression of b1-integrin in freshly isolated
LSK-MPL+ cells (before culture) was set at
1.0. Data represent mean ± SD. Data are repre-
sentative of three independent experiments
(A–D).of THPO/MPL signaling did not enhance LTR activity of
LSKCD34+MPL+ cells after 2 days of cultivation (data
not shown). We speculate that self-renewal capacity and
the efficient LTR activity might be enhanced, provided
the adequate cell-adhesion molecules and interaction
with extracellular matrix had existed in culture condition.
If so, optimization of culture condition including artificial
extracellular matrix and other niche factors must be nec-
essary to reproduce niche environment in vitro that maxi-
mizes the intrinsic capability of HSCs. Combinational
treatment of SCF with THPO suppressed p57Kip2 and
Tie2 in LSKCD34MPL+ cells, while THPO suppressed
SCF-induced upregulation of c-Myc. These data suggest
that THPO/MPL signaling is associated with the regulation
of cell-cycle-regulator expression in LT-HSCs. We hy-
pothesized from these findings that THPO/MPL signaling
is involved in the maintenance of quiescence of LT-HSCs.
THPO/MPL Signaling Is Required for the
Maintenance of Quiescence of LT-HSCs
In order to examine the role of THPO/MPL signaling in the
maintenance of quiescent HSC, we treated mice with
AMM2 and analyzed the cell-cycle status of LT-HSCs.
This treatment slightly decreased the platelet counts on
day 6 (Figure S2) but did not induce apoptosis of LSK cells
(data not shown). It was previously reported that pyronin Y
(PY)low/ and PY+ cells were in G0 and G1 phases of cell
cycle, respectively (Hu¨ttmann et al., 2001). Then, we in-
vestigated the effect of AMM2 treatment on the cell-cycle
status of LT-HSCs by PY staining. Consistent with previ-
ous reports (Yamazaki et al., 2006), most LSKCD34 cells
are PYlow/, suggesting that these cells are in the G0690 Cell Stem Cell 1, 685–697, December 2007 ª2007 Elsevierphase of the cell cycle in the steady state. On day 6 of
AMM2 injection, AMM2 treatment dose-dependently in-
creased the PY+ fraction in LSKCD34 cells (Figures 6A
and 6B). These data suggest that the inhibition of THPO/
MPL signaling results in reduction of the quiescent HSC
population. In addition, the proportion of SP cells in LSK
cells was reduced concomitantly with the increase of
PY+ cells after 6 days of AMM2 injection (Figure 6C,
Figure S3). In contrast to the AMM2, the inhibition of
SCF/c-Kit signaling by anti-c-Kit neutralizing Ab, ACK2,
did not affect PY population in LSKCD34 cells but re-
duced PY+ fraction in LSKCD34+ cells (Figure S4). In addi-
tion, ACK2 treatment reduced non-SP in LSK cells on
day 3 (Figure S4).
From these data above, we hypothesized that blocking
THPO/MPL signals influence not only the cell cycle but
also HSC-niche interactions. To clarify this issue, we ex-
amined whether AMM2 administration enables HSCs to
engraft under nonmyeloablative conditions (Figures 6D
and 6E). Since it is likely that a transition of the cell popu-
lation from non-SP to SP cells would disturb engraftment
of the donor HSCs, we administered a low dose of 5-FU to
deplete the endogenous cycling HSCs. As shown in
Figure 6E, only combined administration of AMM2 and
5-FU enabled donor-derived cells to be engrafted in recip-
ient BM (recipient mice positive for lymphomyeloid recon-
stitution, five of five), while efficient engraftment of donor
LSK cells was not observed with other pretreatments
(PBS alone, zero of five; 5-FU alone, one of five; AMM2
alone, zero of five). These data suggest that inhibition of
THPO/MPL signaling reduced the number of quiescent
LT-HSCs and allowed exogenous HSC engraftmentInc.
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Regulation of Quiescent HSCs by THPOFigure 5. Expression of Cell-Cycle-Related Genes
(A) LSK cells were sorted 6 days after AMM2 injection and after 4 days of daily THPO injection. Relative expression of Cdkns (p21Cip1, p27Kip1, and
p57Kip2), c-Myc, and Tie2 was analyzed. Data represent mean ± SD from separate experiments (*p < 0.01, **p < 0.05, compared to PBS).
(B) LSKCD34MPL+ and LSKCD34+MPL+cells were sorted and cultured and analyzed the expression of p21Cip1, p27Kip1, p57Kip2, c-Myc, and Tie2.
Data represent mean ± SD (*p < 0.01, **p < 0.05, compared to before culture in each group).without irradiation. These findings support the idea that
THPO/MPL signaling is important for maintaining quies-
cent HSC population in the steady state in vivo.
On the other hand, a continuous administration of
AMM2 did not enable the engraftment of donor-derived
LSK cells (Figure 6E). In serum-free culture with SCF and
THPO in vitro, AMM2 transiently increased BrdU incorpo-
ration of LSK cells, while the number of expanded cells
was eventually reduced by AMM2 on day 4 of culture
(Figure S5). We assume that residual AMM2 in the periph-
eral circulation of recipient mice negatively affected post-
BMT expansion of donor cells, as shown in Figure 6E.
Stimulation of THPO/MPL Signaling Transiently
Increased the Proportion of Quiescent HSCs
Next, we analyzed the proportion of LSK-SP cells after
THPO injection in mice. After 2 days of THPO injection,
the proportion of SP increased, and the proportion of
non-SP decreased in LSK cells. The ratio of SP/non-SP
in LSK increased 2-fold by the THPO treatment (Figures
7A and 7B). In particular, the ratios of tip to basal SP in-
creased 2.4-fold and 2.0-fold in LSK-SP cells on days 2
and 4 after THPO treatment, respectively (Figure 7B). In-
creases of the ratio of SP to non-SP and tip to basal-SP
by THPO treatment indicates the possibility that some cy-
cling HSCs convert to quiescent phenotype. In addition,Cell Spretreatment with THPO (12 hr prior to 5-FU injection) en-
hanced 5-FU resistance of LSK-MPL+ cells on day 2 post-
5-FU injection, compared to PBS treatment (Figure S6).
The higher number of LSK-MPL+ cells survived when
a higher dose of THPO (100 mg/kg) was administrated. In
particular, MPLhigh fraction in LSK survived preferentially
by THPO. THPO treatment increased the number of LSK
cells 4 days after injection, and the ratio of SP to non-SP
cells was decreased on day 4. On day 6, the ratio of SP/
non-SP and tip/basal SP and the number of LSK cells
were returned to the normal level (Figure 7B and data
not shown). Continuous daily injection of THPO also in-
creased the proportion of LSK-SP cells (Figure 7C). The
ratio of SP to non-SP in LSK cells increased 2.3-fold on
day 4 after THPO injection compared to PBS treatment
(Figure 7D). On day 6 of daily THPO treatment, the ratio
of SP to non-SP on LSK cells was decreased due to the
increase of the number of LSK cells (Figure 6D). Platelet
counts also increased following THPO injection
(Figure S2). To examine whether the SP cells after THPO
treatment maintained quiescence, we analyzed the cell
cycle of LSK-SP and LSKCD34 cells. Both SP and
CD34 fraction in LSK cells maintained quiescence 2
days after 100 mg/kg of THPO injection (Figure 7E). On
the other hand, a higher dose of THPO administration in-
creased the proportion of PY+ fraction in LSKCD34 andtem Cell 1, 685–697, December 2007 ª2007 Elsevier Inc. 691
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(A) PY analysis of LSKCD34 cells after AMM2 treatment. Inhibition of MPL increased the frequency of PY+ cells in LSKCD34 fraction. Data represent
mean ± SD (n = 6 per group).
(B) Hoechst and PY staining emission patterns of LSKCD34 cells.
(C) Percentages of SP cells in LSK cells after 6 days of AMM2 treatment. AMM2 decreased SP cells in LSK cells in a dose-dependent manner. Data
represent mean ± SD (n = 5 per group).
(D) Experimental procedure of BMT without irradiation. Left box shows a single injection of AMM2 or PBS 6 days before BMT. Right box indicates daily
administration of AMM2. On day 5, mice were treated with 5-FU or PBS injection. On day 7, Ly5.1+ 1x104 LSK cells were injected into each group
without X-ray irradiation.
(E) Inhibition of THPO/MPL signaling by AMM2 permits BMT without irradiation. Percentages of donor-derived cells in peripheral blood are shown.
Data represent mean ± SD (n = 5 per group).LSK-SP cells on day 2 (Figure 7F and data not shown), in-
dicating that a high dose of THPO rapidly induced prolifer-
ation of HSCs.
DISCUSSION
THPO is known to be the primary cytokine regulating
megakaryocyte development and platelet production,
and it is involved in regulation of survival and proliferation
of HSCs (Alexander et al., 1996; Borge et al., 1996; Kimura
et al., 1998; Solar et al., 1998; Fox et al., 2002). In addition,
THPO/MPL signaling synergistically induced HSC prolifer-
ation with other cytokines (Sitnicka et al., 1996; Ema et al.,
2000). In this study, we demonstrate that THPO/MPL sig-
naling is involved in the niche regulation of LT-HSCs,
maintaining quiescent population of HSCs in the osteo-692 Cell Stem Cell 1, 685–697, December 2007 ª2007 Elsevierblastic niche. Currently, the stem cell niches for hemato-
poietic system were identified in two sites in the BM:
one at the endosteal surface and the other in sinusoidal
vascular areas (Calvi et al., 2003; Zhang et al., 2003; Arai
et al., 2004; Kiel et al., 2005), and it has been proposed
that the osteoblastic niche is thought to maintain HSC qui-
escence over the long term (Yin and Li, 2006). In addition,
it was reported that CXCL12-abundant reticular cells as-
sociated with HSCs in both the vascular and the osteo-
blastic niche (Sugiyama et al., 2006).
Quiescence of HSCs is critical to ensure lifelong hema-
topoiesis and to protect the HSC pool from myelotoxic in-
sult and premature exhaustion under conditions of hema-
topoietic stress (Cheng et al., 2000). Here we showed that
MPL was expressed in the LT-HSC fractions (Figures 1
and 3), and MPL expression in HSCs is closely correlatedInc.
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FACS analysis of the frequency of quiescent HSCs after stimulation of THPO/MPL signaling by exogenous administration of THPO.
(A) Representative FACS profiles of LSK-SP cells after 2 days of THPO injection.
(B) Ratio of SP to non-SP fraction in LSK after THPO injection (left). Ratio of tip (gate i) to basal (gate ii) portion of LSK-SP fraction after THPO injection
(right). Data represent mean ± SD (n = 4 per group).
(C) Proportion of LSK-SP cells after continuous daily THPO injection. THPO transiently increased the proportion of SP cells 2–4 days after the first
injection (left). Data shown are the fold increase of the SP fraction in LSK cells mediated by THPO compared to PBS treatment. Data represent
mean ± SD (n = 4 per group). Representative FACS profiles of LSK-SP after 4 days of daily THPO treatment are shown (right).
(D) Fold increase in the ratio of SP/non-SP between PBS and THPO treatments. Data represent mean ± SD (n = 4 per group).
(E) PY analysis of LSK-SP and LSKCD34 cells after 2 days of THPO administration. LSK-SP (Ea) and LSKCD34 cells (Eb) maintained the quiescence
after 2 days of THPO treatment. Data represent mean ± SD (n = 4 per group). Hoechst and PY staining emission pattern of LSK-SP cells (Ec).
(F) The percentages of PY+ fraction in LSKCD34 cells. High dose of THPO increased PY+ fraction in LSKCD34 cells. Data represent mean ± SD
(n = 4 per group).with cell-cycle status (Figure 1). MPL+ HSCs closely con-
tacted to THPO-producing osteoblastic cells at the end-
osteal surface in the trabecular bone area (Figure 2), indi-
cating that THPO/MPL signaling is involved in the niche
regulation of LT-HSCs in the osteoblastic niche, such as
Ang-1/Tie2 (Arai et al., 2004), Jagged1/Notch1 (Calvi
et al., 2003), N-cadherin (Zhang et al., 2003), or osteopon-
tin (Nilsson et al., 2005; Stier et al., 2005). In addition, we
found that THPO/MPL signaling upregulated b1-integrin
(Figure 4D). These data suggest that THPO/MPL signal-
ing-induced cell adhesion of LT-HSCs to the osteoblastic
niche may contribute to the maintenance of quiescent
HSCs. Moreover, AMM2 and THPO treatment revealedCellthat THPO/MPL signaling is involved in the regulation of
cell-cycle-regulator expression, such as p21Cip1, p57Kip2,
c-Myc, and Tie2 (Figure 5). Especially, we found that
THPO treatment increased and AMM2 treatment de-
creased the expression of p57Kip2, which is highly ex-
pressed in the quiescent population in LT-HSCs
(Figure 1D and 5 and Figure S1). In the accompanying pa-
per, Qian et al. (2007) clearly show that p57Kip2 is dramat-
ically downregulated in THPO/ HSCs. The reduction of
p57Kip2 expression in HSCs by AMM2 treatment is consis-
tent with the data of THPO/ HSCs (Qian et al., 2007).
It has been reported that p57Kip2 forms a complex with
cyclin D1, which is essential for HSC expansion, in theStem Cell 1, 685–697, December 2007 ª2007 Elsevier Inc. 693
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zaki et al., 2006). Scandura et al. (2004) reported a result
of microarray analysis using primary human hematopoi-
etic cells, showing that p57Kip2 is the only Cdkn induced
by TGF-b. Unexpectedly, TGF-b receptor null BM did
not show significant abnormalities in HSC function (Lars-
son et al., 2003). Therefore, we hypothesize that the com-
bined activities of cell-cycle-regulator and cell-adhesion
molecules play an important role in regulation of THPO/
MPL-mediated HSC maintenance. It remains to elucidate
the function of p57Kip2 in quiescent HSCs.
Administration of AMM2 decreased the number of
quiescent population in LT-HSCs. In contrast, ACK2
decreased the cycling HSCs and progenitor cells
(Figure S4). It is known that dormant primitive stem cells
are resistant to ACK2 (Kodama et al., 1992; Nishimura
et al., 2002). Therefore, we hypothesize that THPO/MPL
signaling takes part in the maintenance of a quiescent
population, and the postnatal reduction of the HSC pool
in MPL- or THPO-deficient mice might be due to continu-
ing defects in quiescence of LT-HSCs. Indeed, Qian et al.
(2007) clearly show the age-progressive loss of LT-HSC in
THPO/ mice. This reduction in the LT-HSCs in THPO/
mice is accompanied by the accelerated HSC cell cycling.
In the serum-free culture, AMM2 initially enhanced BrdU
incorporation of HSCs, whereas it reduced proliferation
of cells on day 4 of culture (Figure S5). The enhanced
BrdU incorporation in response to AMM2 initially might re-
flect the ability of THPO to promote quiescence of HSCs;
however, on day 4, most of the cells in cultures are not
stem cells, and the reduced proliferation might reflect
that the effect of THPO on more committed progenitors
is to enhance proliferation rather than quiescence. We
speculate that THPO-induced quiescence is HSC spe-
cific. Furthermore, by administrations of AMM2 and
5-FU together in recipient mice, donor LSK cells were
able to engraft without lethal radiation (Figure 6), indicating
that inhibition of THPO/MPL signaling reduces HSC-niche
interactions. It suggests that inhibiting the HSC-niche in-
teraction represents a novel technique for BMT without ir-
radiation. To attain a better engraftment without myeloa-
blative conditioning, it is critical to inhibit the interaction
of endogenous HSC with the niche effectively after
AMM2 treatment. One prediction would be that simulta-
neous use of G-CSF with AMM2 has a potential to induce
efficient mobilization of HSCs to peripheral blood and en-
able higher engraftment. Further investigations are neces-
sary to clarify this issue. On the other hand, we found that
the continuous injection of AMM2 did not allow nonmye-
loablative BMT. We hypothesize that THPO/MPL signaling
is also involved in HSC proliferation for replenishment of
BM cellularity during an initial rapid cycling and expansion
phase of BMT. Fox et al. (2002) previously reported that
THPO expands HSCs after BMT. In addition, Qian et al.
(2007) also clearly demonstrated that THPO/-recipient
mice showed the defects in posttransplantation expan-
sion of donor HSCs and clarified that the expansion of
HSCs in the first weeks after transplantation is highly
THPO dependent.694 Cell Stem Cell 1, 685–697, December 2007 ª2007 ElsevierWe also found that THPO administration transiently
increased a quiescent population of HSCs (Figure 7).
The regulation of HSC itself and reproduction of the niche
is of considerable importance for establishment of optimal
condition of the ex vivo expansion of LT-HSCs.
Altogether, our data suggest that the THPO/MPL path-
way is a component of the HSC osteoblastic niche and
propose a novel biphasic mechanism of THPO/MPL sig-
naling for the regulation of LT-HSCs in the niche. THPO
and MPL interaction not only regulates self-renewal but
also quiescence of HSCs in adult BM. In the steady condi-
tion, THPO/MPL pathway participates in the maintenance
of quiescent HSCs and HSC-niche interactions.
It has been discussed lately that stem cell niche is the
potential target of the stem cell-based therapy (Adams
et al., 2007). Our data show the possibility that THPO/
MPL pathway becomes an attractive target to niche ther-
apy. The result of our nonmyeloablative BMT assay allows
us to foresee the possibility that the manipulation of the
components of leukemic stem cell (LSC) niche contributes
to a new strategy for leukemic therapy. It is possible that
possession of the stem cell niche by LSCs causes the re-
sistance to anticancer drugs. Therefore, inhibition of niche
factors may induce the detachment of LSC from the niche
and enhance sensitivity to the anticancer therapy. Identifi-
cations of LSC niche and their niche component are im-
portant issues for this end.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6 (B6-Ly5.2) mice were purchased from Japan SLC (Shizuoka,
Japan). C57BL/6 mice congenic for the Ly5 locus (B6-Ly5.1) were pur-
chased from Sankyo-Lab Service (Tsukuba, Japan). Animal care in our
laboratory was in accordance with the guidance of Keio University for
animal and recombinant DNA experiments.
Antibodies
The following mAbs were used for FACS analysis and cell sorting: anti-
c-Kit (2B8, BD Biosciences), anti-Sca-1 (E13-161.7, BD Biosciences),
anti-CD4 (L3T4, BD Biosciences), anti-CD8 (53-6.72, BD Biosciences),
anti-B220 (RA3-6B2, BD Biosciences), anti-TER-119, Gr-1 (RB6-8C5,
BD Biosciences), anti-Mac-1 (M1/70, BD Biosciences), anti-FLT3
(A2F10.1, BD Biosciences), anti-CD34 (RAM34, eBioscience), anti-
Tie2 (TEK4), and anti-MPL (AMM2). A mixture of CD4, CD8, B220,
TER-119, Mac-1, and Gr-1 was used as the lineage mix (Lin). The fol-
lowing Abs were used for immunohistochemistry: anti-MPL (AMM2),
anti-c-Kit polyclonal Ab (R & D Systems), anti-Tie2 (BD Biosciences),
anti-THPO (donated from Kirin Brewery Co., Ltd), and anti-ALP (B4-
48, R & D Systems). AMM2 and anti-c-Kit Abs (ACK2, eBioscience)
were used for in vivo administration to inhibit THPO/MPL and SCF/c-
Kit signaling, respectively.
Preparation of Rat Monoclonal Abs against Mouse c-MPL
Male Wistar rats (7-week-old) were first immunized intraperitoneally
and via the hindfoot pad with 100 mg of soluble, recombinant extracel-
lular domain of mouse c-MPL and received three further intraperitoneal
injections of 10 mg of the same protein with 2 week intervals. Four days
after the final injection, spleen cells from immunized rats were fused
with P3X63-Ag.8.653 cells and a murine myeloma cell line and cultured
in hybridoma selection medium. Hybridomas were screened for pro-
duction of rat antibodies against mouse c-MPL with a cell-based en-
zyme-linked immunosorbent assay using FDCP2 cells overexpressingInc.
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and designated AMM1-6. Antibodies were tested for their ability to in-
hibit mouse THPO-induced growth of FDCP2 cells expressing mouse
MPL and megakaryocyte colony formation (Figure S7). AMM2 had the
most potent neutralizing activity.
Cell Preparation and Flow Cytometry
Eight-week-old mouse-derived BM cells were fully flushed from fe-
murs and tibias, and mononuclear cells (MNCs) were isolated using
density centrifugation with Lymphoprep (Axis-Shield). Procedures for
SP staining, PY staining, and immunofluorescence staining were pre-
viously described (Arai et al., 2004). Stained cells were analyzed and
sorted by FACSvantage DiVa (Becton Dickinson). The expression of
MPL in LSK cells was analyzed at 2 and 6 days after 5-FU treatment
(150 mg/kg body weight, i.v.).
Immunohistochemistry
Procedure for preparation of BM sections, BrdU-LTR assay, and im-
munohistochemistry of tissue sections has been previously described
(Arai et al., 2004). For nuclear staining, specimens were treated with
TOTO3 (Molecular Probes). Fluorescence images were obtained
by using a confocal laser-scanning microscope (Olympus, model
FV1000).
Culture of Cell Lines and Primary Osteoblastic Cells
OP9 stromal cells were maintained as previously described (Arai et al.,
2004). NIH 3T3 were maintained in DMEM (Sigma) supplemented with
10% FCS at 37C in humidified 5% CO2 air. Isolation and maintenance
of adult mouse BM-derived primary osteoblastic cells were described
previously (Arai et al., 2004).
In Vitro Cell Cultivation
LSKCD34+MPL+ cells and LSKCD34MPL+ cells were sorted and cul-
tured on fibronectin-coated plate. Cultures were maintained in SF-O3
medium (Sanko Junyaku Co., Ltd.) containing 1.0% BSA 100 ng/ml
SCF and/or 100 ng/ml THPO. After 2 days of cultivation, cells were
collected, and total RNA was isolated using the RNeasy Mini Kit
(QIAGEN). Isolated RNA was reverse transcribed using Advantage
RT-for-PCR Kit (Clontech).
BM Reconstitution Assay
Cells (2 3 103) of LSK-MPL+ and LSK-MPL cells were sorted from
8-week-old Ly5.1 mice BM and transplanted into lethally irradiated
Ly5.2 mice with 2 3 105 competitor cells (Ly5.2). Cells (1 3 102)
of LSKCD34MPL+, LSKCD34+MPL+, LSKCD34MPL, and
LSKCD34+MPL cells were also sorted from 8-week-old Ly5.1 mice
and transplanted into Ly5.2-recipient mice with 2 3 105 competitor
cells. Percentages of donor-derived cells were analyzed monthly by
FACS. Reconstitution of donor (Ly5.1) myeloid and lymphoid cells
was monitored by staining blood cells with antibodies against Ly5.2,
Ly5.1, CD3, B220, Mac-1, and Gr-1. For serial BMT assay, BMMNCs
(5 3 105) or LSK cells (5 3 103) were isolated from four primary recip-
ient mice after 6 months of the first BMT and were transplanted to le-
thally irradiated Ly5.2-recipient mice. For BMT assays without X-ray
irradiation, recipient mice were treated with single injection of AMM2
(1 mg/kg body weight, i.v.) or PBS 6 days before BMT. Simultaneously,
another group of recipient mice was treated with 6 days of daily admin-
istration of AMM2. On day 5, recipient mice were treated with 5-FU
(150 mg/kg body weight, i.p.) or PBS injection. On day 7, Ly5.1+ 1 3
104 LSK cells were injected into each group without X-ray irradiation
(Figure 6D).
In Vivo Assay of THPO/MPL Signaling
To inhibit THPO/MPL signaling in vivo, mice were treated with AMM2
(0.1 or 10 mg/kg body weight, i.v.). To stimulate THPO/MPL signaling
in vivo, mice were treated with single or continuous daily injection of
THPO (100 mg/kg body weight, i.v.). After 2, 4, and 6 days of AMM2
or THPO treatment, LSK-SP cells were analyzed. In order to analyzeCellthe gene expression induced by AMM2 or THPO treatment, LSK cells
were sorted after 6 days of AMM2 (1 mg/kg body weight, i.v.) injection
or after 4 days of daily THPO (100 mg/kg body weight, i.v.) injection.
mRNA expressions were analyzed by qPCR.
Quantitative Real-Time PCR Analysis
A quantitative real-time PCR (qPCR) assay was performed on an ABI
7500 Fast Real-Time PCR System using TaqMan Fast Universal PCR
master mixture (Applied Biosystems, Foster City, CA). Probes and
primers used in qPCR assay are listed in the Supplemental Data.
Data were analyzed by 7500 Fast System SDS Software 1.3.1. All ex-
periments were done in triplicates.
Statistical Analysis
The significance of differences among groups was determined by two-
tailed Student’s t test.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://
www.cellstemcell.com/cgi/content/full/1/6/685/DC1/.
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